EligibleTrials

Molecular Signatures in Inflammatory Skin Disease

Recruiting · NCT03358693 · Observational (researchers observe without assigning treatment) · Lead sponsor: Prof. Dr. Stephan Weidinger

View the official record on ClinicalTrials.gov →
EczemaPsoriasis

Interventions studied

AbrocitinibAnti-IL12/23Anti-IL17Anti-IL23Anti-TNFBaricitinibDupilumabLebrikizumabNemolizumabTralokinumabUpadacitinib

What this trial is about

This pilot project intends to examine the utility of a systems medicine approach to identify regulatory networks and their perturbation in psoriasis and atopic dermatitis, and to obtain a comprehensive perspective on disease and disease control by integrating and modelling data across multiple cellular levels and time following specific blockade of single pathophysiological factors through use of licensed biologics during routine care as systems biology challenge. To this end, ultra-deep phenotyping and prospective molecular characterization in short time-intervals and different disease equilibrium states will be carried out in targeted small sets of patients. The different layers and types of clinical and molecular information will then be integrated (integrative personal omics profiling iPOP) for generating insights into disease pathways and for extraction of molecular signatures that correspond to clinical severity scores. It will provide a good starting point for planning future trials aimed at identifying biological patterns useful for guiding targeted treatment.

Who can take part

Age range
No age limits stated
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)

Inclusion criteria

Exclusion criteria

Where it is running

2 locations listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.